Although MG132, a constitutive proteasome inhibitor, was the least specific NFκB inhibitor that we examined, it showed effective suppression of NMO IgG-induced NFκB signaling and concomitant chemokine release. Here, NFKB1 is linked to neuromyelitis optica.